Navigate
X
    QualityStocks
  • 18 years ago

VIA Pharmaceuticals, Inc. (NASDAQ: VIAP)

VIA Pharmaceuticals, Inc. (NASDAQ: VIAP) is focused on developing a pipeline of small-molecule drugs designed to target a substantial, but unmet medical need – reducing inflammation in the blood vessel wall. This is known as an underlying cause of atherosclerosis and its complications, including heart attack and stroke. VIA-2291, the company’s lead drug candidate, is currently in a number of Phase 2 clinical trials in patients with cardiovascular disease. For further information, visit the Company’s web site at www.viapharmaceuticals.com.

Tags Rodman & Renshaw
Related Post
  1. Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

    In the United States alone, close to one million people are living with MS, with…

  2. Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step

    California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…

  3. Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership

    The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…